SourcingLink.net announced that it signed a Letter of Intent to collaborate with NanoSmart Pharmaceuticals, Inc. The collaboration includes co-development and an exclusive, world-wide license for specific formulations to treat cancer utilizing NanoSmart's proprietary ‘targeted’ drug delivery system that is designed to enhance delivery of drugs to a wide variety of cancer tumors. SourcingLink.net is excited about the collaboration opportunity because new or already-approved chemotherapy drugs can be reformulated with greater efficacy and safety for treating cancer patients. The company believes that the reformulated drugs, subject to approval by the FDA and/or regional regulatory bodies, may be used as a monotherapy, or as a ‘combo-therapy’ with SNET’s autologous cellular immuno-therapy approach, or with other therapies such as immune check point inhibitors. SNET expects to enter into a full exclusive ‘world-wide’ licensing and co-development agreement with NanoSmart under the terms of the Letter of Intent signed on February 25, 2019. The use of NanoSmart's enhanced drug delivery platform combined with pharmacogenomics and liquid biopsy for personalizing the therapy should augment cancer drug effectiveness and safety, and improve treatment monitoring. Currently, SNET is focused on developing its ‘core’ autologous extracorporeal immuno-therapy device for a durable response.